Supreme Court Rules Generics Not Liable for Pharmacists' Prescribing
The Supreme Court ruled generic drugmakers can't be liable for pharmacists' prescription choices.
Why it matters: This ruling limits pharmaceutical manufacturers' liability related to pharmacists' prescribing decisions, shaping legal risks in healthcare and IP law for drug companies and counsel.
- On June 4, 2026, the Supreme Court unanimously ruled in favor of Hikma Pharmaceuticals USA Inc., rejecting patent infringement claims by Amarin Pharma Inc.
- Hikma used a 'skinny label' for its generic Vascepa, excluding patented cardiovascular indications but including approved uses.
- Justice Jackson emphasized that inducement requires active encouragement, not just compliance with industry standards.
- The ruling overturns a Federal Circuit decision that allowed allegations of inducement based on Hikma's labeling and statements.
On June 4, 2026, the U.S. Supreme Court issued a unanimous 9-0 decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., holding that Hikma did not induce infringement of Amarin's patents related to the cardiovascular use of Vascepa.
Hikma's generic version of Vascepa, FDA-approved in 2020, employed a 'skinny label' that omitted the patented cardiovascular indication while including non-patented approved uses. The Federal Circuit had previously found that Amarin plausibly alleged inducement of infringement due to Hikma's labeling and public statements encouraging doctors to prescribe the generic for the patented use.
Justice Ketanji Brown Jackson, writing for the Court, clarified that inducement of patent infringement requires "active steps" to encourage wrongdoing. Simply following industry norms does not satisfy this threshold. This effectively shields generic drugmakers from liability tied to pharmacists' decisions to prescribe off-label uses.
The ruling impacts pharmaceutical litigation by making it more difficult for brand-name companies to block generic competition through patent claims tied to off-label prescribing. As noted by James Gelfand, President of The ERISA Industry Committee, "Today’s 9-0 decision is a victory for every American worker and employer who relies on access to affordable prescription drugs." Meanwhile, legal experts like Deepro Mukerjee of Katten Muchin Rosenman caution that induced infringement claims against generics are not over but now demand concrete allegations of encouragement beyond mere market participation.
This decision reinforces the viability of the 'skinny label' pathway, allowing generics to enter markets sustainably for non-patented uses without incurring liability for patented indications, balancing patent protections with access to lower-cost medications.
By the numbers:
- 9-0 — Supreme Court unanimous ruling in favor of Hikma Pharmaceuticals
- 2020 — FDA approval year of Hikma's generic Vascepa
- June 4, 2026 — Date of Supreme Court decision
Yes, but: While this ruling restricts liability for generic manufacturers, induced infringement claims against generics remain possible if there is clear evidence of active inducement beyond standard labeling practices.
What's next: Expect shifts in pharmaceutical patent litigation strategies, with brand-name companies needing stronger evidence to claim induced infringement in skinny label cases.